Semin Neurol 2001; 21(1): 009-014
DOI: 10.1055/s-2001-13114
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Dopamine Agonists

Paul Tuite, Brenda Ebbitt
  • Department of Neurology, University of Minnesota, Minneapolis, Minnesota
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Preview

ABSTRACT

Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ropinirole) and apomorphine, another agonist presently under investigation, are discussed.

REFERENCES